title: Neuroleptic malignant syndrome associated with clozapine use.
abstract: Clozapine, an atypical antipsychotic drug, is indicated for severely ill schizophrenic patients refractory to treatment with conventional neuroleptics. One advertised advantage of clozapine is the absence of associated neuroleptic malignant syndrome (NMS). On the basis of a clinical case, the authors question this claim. They are concerned that this potentially fatal condition may be misdiagnosed if physicians are not aware of possible NMS associated with the use of clozapine.
authors.affiliation: Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa.
authors.forename: E S
authors.initials: ES
authors.lastname: Anderson
authors.forename: P S
authors.initials: PS
authors.lastname: Powers
mesh_terms: D000328:Adult; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000523:psychology
chemical_list: D003024:Clozapine